A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 25 Feb 2018
At a glance
- Drugs Ruxolitinib (Primary) ; Sonidegib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 13 Jan 2018 The study has been completed in Germany.
- 23 Jun 2017 Planned End Date changed from 30 Jun 2017 to 29 Dec 2017.
- 23 Jun 2017 Planned primary completion date changed from 30 Jun 2017 to 29 Dec 2017.